AU2002344959A1 - Use of fasl for the treatment of neurodegenerative diseases - Google Patents

Use of fasl for the treatment of neurodegenerative diseases

Info

Publication number
AU2002344959A1
AU2002344959A1 AU2002344959A AU2002344959A AU2002344959A1 AU 2002344959 A1 AU2002344959 A1 AU 2002344959A1 AU 2002344959 A AU2002344959 A AU 2002344959A AU 2002344959 A AU2002344959 A AU 2002344959A AU 2002344959 A1 AU2002344959 A1 AU 2002344959A1
Authority
AU
Australia
Prior art keywords
fasl
treatment
neurodegenerative diseases
neurodegenerative
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002344959A
Inventor
Nikolai Rainov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2002344959A1 publication Critical patent/AU2002344959A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
AU2002344959A 2002-05-03 2002-05-03 Use of fasl for the treatment of neurodegenerative diseases Abandoned AU2002344959A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2002/004894 WO2003092723A1 (en) 2002-05-03 2002-05-03 Use of fasl for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
AU2002344959A1 true AU2002344959A1 (en) 2003-11-17

Family

ID=29286079

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002344959A Abandoned AU2002344959A1 (en) 2002-05-03 2002-05-03 Use of fasl for the treatment of neurodegenerative diseases

Country Status (2)

Country Link
AU (1) AU2002344959A1 (en)
WO (1) WO2003092723A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2064235A1 (en) 2006-09-19 2009-06-03 DKFZ Deutsches Krebsforschungszentrum The death receptor cd95 controls neurogenesis of adult neural stem cells in vivo and in vitro
WO2020041791A1 (en) * 2018-08-24 2020-02-27 Locana, Inc. Fasl immunomodulatory gene therapy compositions and methods for use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997038707A1 (en) * 1996-04-17 1997-10-23 Cytotherapeutics, Inc. Method and device for delivery of apoptosis-inducing molecules
WO1997039629A1 (en) * 1996-04-25 1997-10-30 Genetic Therapy, Inc. Viral vectors including polynucleotides encoding neurotrophic factors and uses therefor
KR20010033834A (en) * 1998-01-02 2001-04-25 타이탄 파마슈티칼스 인코퍼레이티드 Use of pigmented retinal epithelial cells for creation of an immune privilege site

Also Published As

Publication number Publication date
WO2003092723A1 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
AU2003286567A1 (en) Methods for the treatment of skin disorders
AU2003300791A1 (en) Combination therapy for the treatment of pain
AU2003291992A1 (en) Phenylethanolamine derivatives for the treatment of respiratory diseases
AU2003285091A1 (en) Interferon antagonists useful for the treatment of interferon related diseases
WO2003033720A8 (en) Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
AU2003228819A1 (en) Combinations for the treatment of inflammatory skin disorders
AU2003279442A1 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
GB0329874D0 (en) Compounds useful for the treatment of diseases
AU2003286728A1 (en) Compounds for the treatment of metabolic disorders
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
GB0213869D0 (en) The treatment of pain
AU2003251875A1 (en) Combination therapy for the treatment of neoplasms
AU2003904328A0 (en) Diagnosis and treatment of neurodegenerative disorders
AU2003265842A1 (en) Anabaseine derivatives useful in the treatment of neurodegenerative diseases
AU2003251904A1 (en) Combinations of drugs for the treatment of neoplasms
AU2002319296A1 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with CGMP regulated processes
AU2003223538A1 (en) Methods for the treatment of cancer
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
AU2003259833A1 (en) Methods of treating neurodegenerative diseases
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
AU2002333510A1 (en) Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases
AU2003266965A1 (en) Use of carboxamides for the treatment of tinnitus
AU2002344959A1 (en) Use of fasl for the treatment of neurodegenerative diseases
GB0201025D0 (en) The treatment of degenerative diseases
AU2003274885A1 (en) Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase